Skip to search formSkip to main contentSkip to account menu

axitinib

Known as: N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide, axitinibum 
An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and… 
National Institutes of Health

Related topics

Related topics

9 relations

Narrower (2)

AG 013736Inlyta

Broader (3)

ImidazolesIndazolesProtein Kinase Inhibitors
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase InhibitionReceptor Tyrosine Kinase Inhibitors [MoA]axitinib 1 MG Oral Tablet [Inlyta]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
This is a repository copy of A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)
BACKGROUND: Preclinical work suggests Src proteins have a role in the development of resistance to vascular endothelial growth… 
Review
2017
Review
2017
Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
2016
2016
Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer.
ABSTRACT Efficacy of anti-PD-1 antibody was demonstrated in a patient with metastatic renal cell cancer on systemic steroids for… 
2015
2015
The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function
Inhibitors of VEGF receptor (VEGFR) signaling such as sorafenib and sunitinib that are currently used in the treatment of… 
2015
2015
Effect of axitinib on the QT interval in healthy volunteers
PurposeAxitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1–3, approved for second-line… 
Highly Cited
2013
Highly Cited
2013
Reduced Immunosuppressive Properties of Axitinib in Comparison with Other Tyrosine Kinase Inhibitors*
Background: Targeted therapies with tyrosine kinase inhibitors (TKIs) are used for the treatment of advanced renal cell carcinoma… 
2011
2011
Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC).
4504 Background: In a global, randomized, phase III trial of axitinib vs sorafenib as second-line therapy for mRCC (Rini et al… 
2011
2011
A randomized phase II study comparing mFOLFOX-6 combined with axitinib or bevacizumab or both in patients with metastatic colorectal cancer (mCRC).
485 Background: Vascular endothelial growth factor receptor inhibitors, including axitinib (AG-013736), may be useful in treating… 
2011
2011
Polymer drug-eluting stents: is the future biodegradable?
Highly Cited
2008
Highly Cited
2008
Axitinib (AG-013736) in patients with metastatic melanoma: A phase II study
9006 Background: No treatment has extended survival in stage IV melanoma. Melanomas are highly angiogenic and metastatic, express… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)